Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Labyrinthitis ossificans is a known complication of bacterial meningitis which results in severe to profound hearing loss. Historically, labyrinthitis ossificans was considered a contraindication for cochlear implantation. However, with advances in technology, cochlear implantation is an accepted treatment for hearing loss in labyrinthitis ossificans.

Materials And Methods: 17 cases with varying degrees of ossification in the cochlea were evaluated and treated at our tertiary referral hospital and cochlear implantation center out of a total of 832 profoundly deaf patients evaluated from January 2007 to June 2023. The etiology, radiology, intra-operative findings and treatment protocols followed in these patients are discussed.

Results: 15 of the 17 patients could successfully be implanted with a cochlear implant, while two were referred to another center for Auditory Brainstem Implantation. The degree/grade of ossification decided the available cochlear lumen for implantation and hence the surgical approach and choice of the electrode.

Conclusion: A protocol for the order of choice of electrode and site of insertion in various cases of labyrinthitis ossificans depending on the degree of ossification is proposed. In the order of preference, it would be thus: 1. Cochlear implantation with the active electrode in the scala tympani of the basal turn; 2. Electrode in the scala vestibuli of the basal turn; 3. Anterograde insertion of the implant from the second turn; 4. Retrograde insertion of the implant from the second turn; 5. Insertion of a split array electrode and finally 6. Auditory brainstem implantation.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14670100.2025.2524953DOI Listing

Publication Analysis

Top Keywords

cochlear implantation
20
labyrinthitis ossificans
12
implantation
8
hearing loss
8
auditory brainstem
8
brainstem implantation
8
electrode scala
8
basal turn
8
insertion implant
8
implant second
8

Similar Publications

Recessive variants in TWNK cause syndromic and non-syndromic post-synaptic auditory neuropathy through MtDNA replication defects.

Hum Genet

September 2025

College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, 28 Fuxing Road, Beijing, 100853, China.

Recessive variants in TWNK cause syndromes arising from mitochondrial DNA (mtDNA) depletion. Hearing loss is the most prevalent manifestation in individuals with these disorders. However, the clinical and pathophysiological features have not been fully elucidated.

View Article and Find Full Text PDF

The Green Cochlea.

Braz J Otorhinolaryngol

September 2025

Clinical Research Department, MED-EL GmbH, Innsbruck, Austria.

Objectives: Healthcare systems contribute significantly to global greenhouse gas emissions through energy consumption and waste generation. This study aims to explore strategies to make cochlear implantation processes more environmentally sustainable and aligned with the United Nations' Sustainable Development Goals.

Methods: We examined various approaches including the use of bio-based and biodegradable materials, sustainable energy solutions, greener anesthetic practices, effective waste separation and recycling in operating rooms, and patient-centered strategies such as reducing travel and promoting early activation and fitting of cochlear implants.

View Article and Find Full Text PDF

BACKGROUND Duplicated internal auditory canal (dIAC) is a rare congenital temporal bone anomaly associated with ipsilateral sensorineural hearing loss (SNHL). The Bonebridge bone conduction implant has a magnet, an internal transducer, and an external audio processor. This report is of a 14-year-old girl with unilateral SNHL and vestibulocochlear nerve (VIII cranial nerve) aplasia due to dIAC who was treated with a Bonebridge bone conduction implant.

View Article and Find Full Text PDF

Objective: This study aims to evaluate long-term auditory outcomes in patients with inner ear malformations (IEMs) treated with cochlear or auditory brainstem implants (CI/ABI), and to assess the influence of anatomical subtype, electrode design, insertion depth, and genetic/syndromic background on hearing performance over a 10-year follow-up.

Methods: We conducted a prospective cohort study including patients with radiologically confirmed IEMs and bilateral severe-to-profound hearing loss, all of whom underwent implantation and completed at least 10 years of follow-up. Outcomes were assessed using pure-tone average (PTA) and speech recognition scores (SRS) at defined intervals.

View Article and Find Full Text PDF

Gene therapy for inner ear disease: the next targets.

Curr Opin Otolaryngol Head Neck Surg

October 2025

Department of Otolaryngology Head and Neck Surgery, University of Vienna, Vienna, Austria.

Purpose Of Review: The recent successful otoferlin gene therapy trials have refocused the fields attention on the potential of gene therapy to cure hearing loss. With over 100 known monogenetic causes of hearing loss, the key question is which will be the next set of disorders that are treatable. The current review addresses potentially targetable hearing disorders that can be addressed with current gene therapy technologies.

View Article and Find Full Text PDF